1255664-48-2 Usage
Uses
Used in Pharmaceutical Synthesis:
(2S,4S)-Methyl4-(benzyloxycarbonylaMino)piperidine-2-carbo-xylate is used as a key intermediate in the synthesis of various pharmaceuticals for its unique chemical properties and potential biological activities.
Used in Organic Compounds Synthesis:
(2S,4S)-Methyl4-(benzyloxycarbonylaMino)piperidine-2-carbo-xylate is used as a building block in the production of various organic compounds, contributing to the development of new chemical entities.
Used in Medicinal Applications:
(2S,4S)-Methyl4-(benzyloxycarbonylaMino)piperidine-2-carbo-xylate is used as a potential therapeutic agent in the treatment of various diseases and disorders, owing to its biological activities and medicinal potential.
Used in Pharmaceutical Industry:
(2S,4S)-Methyl4-(benzyloxycarbonylaMino)piperidine-2-carbo-xylate is used as a key component in the development of new drugs and pharmaceutical formulations, enhancing their efficacy and therapeutic outcomes.
Used in Research and Development:
(2S,4S)-Methyl4-(benzyloxycarbonylaMino)piperidine-2-carbo-xylate is used as a valuable research tool in the exploration of new chemical pathways, mechanisms of action, and potential applications in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1255664-48-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,5,6,6 and 4 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1255664-48:
(9*1)+(8*2)+(7*5)+(6*5)+(5*6)+(4*6)+(3*4)+(2*4)+(1*8)=172
172 % 10 = 2
So 1255664-48-2 is a valid CAS Registry Number.
1255664-48-2Relevant academic research and scientific papers
Karhadkar, Tejas R.,Meek, Thomas D.,Gomer, Richard H.
, p. 106 - 117 (2021)
The active form of transforming growth factor-b1 (TGF-b1) plays a key role in potentiating fibrosis. TGF-b1 is sequestered in an inactive state by a latency-associated glycopeptide (LAP). Sialidases (also called neuraminidases (NEU)) cleave terminal sialic acids from glycoconjugates. The sialidase NEU3 is upregulated in fibrosis, and mice lacking Neu3 show attenuated bleomycin-induced increases in active TGF-b1 in the lungs and attenuated pulmonary fibrosis. Here we observe that recombinant human NEU3 upregulates active human TGF-b1 by releasing active TGF-b1 from its latent inactive form by desialylating LAP. Based on the proposed mechanism of action of NEU3, we hypothesized that compounds with a ring structure resembling picolinic acid might be transition state analogs and thus possible NEU3 inhibitors. Some compounds in this class showed nanomolar IC50 for recombinant human NEU3 releasing active human TGF-b1 from the latent inactive form. The compounds given as daily 0.1–1-mg/kg injections starting at day 10 strongly attenuated lung inflammation, lung TGF-b1 upregulation, and pulmonary fibrosis at day 21 in a mouse bleomycin model of pulmonary fibrosis. These results suggest that NEU3 participates in fibrosis by desialylating LAP and releasing TGF-b1 and that the new class of NEU3 inhibitors are potential therapeutics for fibrosis.
